Joseph Toth

Title: **Joseph Toth: A Pioneer in Glypican-3 and Immunoglobulin Research**

Introduction

Joseph Toth, based in Belmont, Massachusetts, is a notable inventor recognized for his significant contributions to biomedical research through innovative inventions. With three patents to his name, Toth has made strides in developing therapeutic and diagnostic applications that target critical biomarkers.

Latest Patents

Toth's latest patents showcase his expertise in the development of novel molecules. One of his patents includes "Glypican-3-binding fibronectin based scaffold molecules," which details polypeptides encompassing tenth fibronectin type III domains (Fn3) that specifically bind to glypican-3. This invention lays the groundwork for creating fusion molecules that utilize the Fn3 domain for diagnostic and therapeutic purposes, including glypican-3 Fn3 drug conjugates.

Another significant patent involves "Antibodies binding to ILT4," where Toth presents antibodies that bind specifically to immunoglobulin-like transcript 4 (ILT4), known by other names such as LILRB2, LIR2, MIR10, and CD85d. This technology offers potential applications in the development of targeted therapies while ensuring specificity to human ILT4 without significant interaction with other members of the ILT family.

Career Highlights

Throughout his career, Joseph Toth has held key positions in renowned companies like Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. His work in these organizations has contributed to advancements in biopharmaceuticals and therapeutics, focusing on innovative treatments for various medical conditions.

Collaborations

Toth's journey in the field of invention has been marked by collaborations with esteemed colleagues such as Guodong Chen and Richard Y Huang. Together, they have worked to advance the understanding and application of their research, further solidifying Toth's impact on the scientific community.

Conclusion

Joseph Toth's innovative spirit and dedication to research have led to significant advancements in therapeutics involving glypican-3 and ILT4. His patents reflect a commitment to improving healthcare outcomes through targeted therapies, making him a valuable contributor to modern medical science. As he continues his work, Toth's influence is expected to resonate throughout the fields of biomedical research and innovation.